期刊文献+

胰体尾腺癌的外科治疗 被引量:1

Surgical therapy of adenocarcinoma of body and tail of pancreas
原文传递
导出
摘要 目的研究胰体尾腺癌的临床特点、肿瘤行为和外科治疗效果。方法回顾性分析1980年1月至2006年8月我院腹部肿瘤外科收治的有明确病理学诊断的108例胰体尾腺癌病人的临床病理资料。结果84%(91例)为导管腺癌。46%(50例)出现同时性远处转移,血行转移40%(43例)以肝转移为主(41例,38%),种植转移19例(18%)。54%(58例)切除了肿瘤,Ⅰ、Ⅱ、Ⅲ、Ⅳ期病人手术切除率分别为100%(5例)、100%(33例)、5%(1例)和38%(19例),差异显著(x^2= 56.80,P<0.001)。和未切除肿瘤的病人相比,手术切除病人的男性比例(53%;72%,x^2=3.92,P=0.048)显著较少,出现上腹痛(66%:84%,x^2=4.78,P=0.029)、体重下降(22%:42%,x^2= 4.78,P=0.029)和种植转移的比例(0:38%,x^2=26.74,P<0.001)显著较低。Ⅰ、Ⅱ、Ⅲ、Ⅳ期病人中位生存分别为35(11~73)、14(1~83)、6(2~25)和4(1~20)个月,存在显著性差异(x^2=30.07,P<0.001)。Ⅲ、Ⅳ期胰体尾腺癌手术切除后中位生存8(2~25)个月,显著长于未切除病人的4(1~13)个月(x^2=17.06,P<0.001)。结论胰体尾腺癌手术时出现同时性远处转移的几率大。男性、上腹痛、体重下降、种植转移时手术切除的可能性降低。Ⅲ期病人虽然手术切除率较Ⅳ病人为低,但是术后生存无显著差异;对Ⅲ、Ⅳ期胰体尾癌而言,原发灶能够切除的病人术后生存期较长。 Objective To analyze the clinical presentations, oncological behavior of and surgical effects on adenocarcinoma of the left pancreas. Methods The clinical data of 108 patients with adeno- carcinoma of the body and tail of the pancreas treated in our hospital from January 1980 to August 2006 were retrospectively analyzed. Results Ninety-one patients (84%) suffered from ductal adeno carcinoma. Forty-three patients (400/00) had hematogenous metastasis (liver predominantly, n = 41) and 19 (18%) cavity implantation. Fifty eight patients (540/00) underwent tumor removal, and the re moval rate was significantly different among patients with stage Ⅰ (100%, 5/5), Ⅱ (100%, 33/33),Ⅲ(5%, 1/20) and Ⅳ (38%, 19/50) disease(χ^2=56.80,P〈0. 001). There were few male (53% : 72%, χ^2=3.92,P=0.048), less abdominal pain (66% : 84%, χ^2=4.78,P=0.029), weight loss (22% : 42%,χ^2 =4.78,P= 0.029), abdominal and pelvic carcinomatosis (0:38%,χ^2 =26.74, P〈 0. 001) in patients with tumor removal than those without. The median survival was markedly differ ent among patients with stage Ⅰ (35 (11~73) months), Ⅱ (14 (1Ⅱ83) months),Ⅲ (6 (2Ⅲ25) months) and Ⅳ (4 (1~20) months) disease (χ^2 = 30.07, P〈0. 001). Resection of primary tumor could get a median survival of 8 (2~25) months, longer than those could not in stage Ⅲ and Ⅳ disease (χ^2 = 17.06, P〈0. 001 ). Conclusion Concomitant distant metastasis (especially in the liver) was high in adenocarcinoma of the body and tail of the pancreas. Male patients, symptoms such as abdomi nal pain or weight loss, exist of cavity implantation can decrease the resection possibility. Although the resection rate is lower in stage Ⅲ patients than those in stage IV, but there is no significant differ ence in postoperative survival, only those who had their tumor resected can get a longer survival.
出处 《中华肝胆外科杂志》 CAS CSCD 2007年第12期814-817,共4页 Chinese Journal of Hepatobiliary Surgery
关键词 胰腺肿瘤 肿瘤行为 外科治疗 预后 Pancreatic neoplasms The body and tail of the pancreas Clinical manifestation Pathology Surgical treatment Prognosis
  • 相关文献

参考文献11

  • 1Lillemoe KD,Cameron JL.胰腺癌和壶腹周围癌.见:秦兆寅,纪宗正译,梅氏腹部外科手术学(第十版).西安:世界图书版西安公司,2000.2037-2061.
  • 2Exocrine pancreas. In: Greene FL, Page DL, Fleming ID, et al. eds. AJCC Cancer Staging Manual 6^th, Lippincott Raven (PA), 2002. 157-164.
  • 3张群华,倪泉兴,代表中国抗癌协会胰腺癌专业委员会.胰腺癌2340例临床病例分析[J].中华医学杂志,2004,84(3):214-218. 被引量:141
  • 4Fabre JM, Houry S, Manderscheid JC, et al. Surgery for left-side pancreatic cancer. Br J Surg, 1996, 83:1065-1070.
  • 5Sperti C, Pasquali C, Pedrazzoli S. Ductal adenocarcinoma of the body and tail of the pancreas. J Am Coll Surg, 1997, 185: 255-259.
  • 6Burcharth F, Trillingsgaard J, Olsen SD, et al. Resection of cancer of the body and tail of the pancreas. Hepatogastroen terology, 2003, 50: 563-566.
  • 7Christein JD, Kendrick ML, Iqbal CW, et al. Distal pancrea tectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg, 2005, 9: 922-927.
  • 8Shimada K, Sakamoto Y, Sano T, et al. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery, 2006, 139:288-295.
  • 9Kotwall CA, Maxwell JG, Brinker CC, et al. National estimates of mortality rates for radieal pancreatieoduodenectomy in 25000 patients. Ann Surg Oncol, 2002, 9: 847-854.
  • 10季晓昕,李非,孙海晨,崔叶青,刘大川,孙家邦.胰腺癌肝转移体外模型的构建[J].中华肝胆外科杂志,2004,10(12):824-826. 被引量:5

二级参考文献18

共引文献151

同被引文献12

  • 1张太平,赵玉沛.胰腺癌基因治疗的现状与展望[J].中华肝胆外科杂志,2007,13(3):148-151. 被引量:7
  • 2Bilimoria KY,Bentrem DJ,Ko CY,et al.Multimodality therapy for pancreatic cancer in the U.S.:utilization,outcomes,and the effect of hospital volume.Cancer,2007,110:1227-1234.
  • 3Jamal A,Murray T,Samuels A,et al.Cancer statistaics,2003.CA Cancer J Clin,2003,53:5-26.
  • 4Neoptolemos JP,Stocken DD,Dunn JA,et al.Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.Ann Surg,2001,234:758-768.
  • 5Okabayashi T,Nishimori I,Nishioka A,et al.Long-term effects of muhimodal treatment for patients with resectable carcinoma of the pancreas.Oncol Rep,2008,20:651-656.
  • 6Ghaneh P,Smith R,Tudor-Smith C,et al.Neoadjuvant and adjuvant strategies for pancreatic cancer.Eur J Surg Oncol,2008,34:297-305.
  • 7Hansen EK,Roach M.Handbook of Evidence-based Radiation Oncology.Springer,2005.
  • 8Mocrtel CG,Frytak S,Hahn RG,et al.Therapy of locally unresectable pancreatic carcinoma:a randomized comparison of high dose (6000 fads) radiation alone,moderate dose radiation (4000 rads+5-FU),and high dose radiation + 5-FU:The Gastrointestinal Tumor Study Group.Cancer,1981,48:1705-1710.
  • 9Boz G,De Paoli A,Innocente R,et al.Radiotherapy and chemotherapy in pancreatic cancer.Topical issue and future perspectives.JOP,2006,7:122-130.
  • 10Corsini MM,Miller RC,Haddock MG,et al.Adjuvant radiotherapy and chemotherapy for pancreatic carcinorna:the Mayo Clinic experience (1975-2005).J Clin Oncol,2008,26:3511-3516.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部